Back to search

Article

Overcoming rapaprotin resistance through inhibition of P-glycoprotein

2025-09-30

Abstract excerpt

<h4>ABSTRACT</h4> The 26S proteasome is an essential regulator of protein homeostasis and a clinically validated therapeutic target in multiple myeloma (MM). Rapaprotin, a novel macrocycle identified from a rapamycin-inspired rapafucin library, disrupts 26S proteasome function by inducing disassembly of the 19S regulatory particle in the 26S proteasome, leading to apoptosis in MM cells. Its bioactivation requires...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
55841778-37ce-5f1b-9440-791ba0f4eb52
DOI
10.1101/2025.09.28.679086
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Overcoming rapaprotin resistance through inhibition of P-glycoproteinDOI 10.1101/2025.09.28.679086
Different Strategies to Overcome Resistance to Proteasome Inhibitors—A Summary 20 Years after Their IntroductionSemantic proximity
Inhibition of p-glycoprotein does not increase the efficacy of proteasome inhibitors in multiple myeloma cellsSemantic proximity
RETRACTED: A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells.Semantic proximity
Novel Anti-B-cell Maturation Antigen Alpha-Amanitin Antibody-drug Conjugate HDP-101 Shows Superior Activity to Belantamab Mafodotin and Enhanced Efficacy in Deletion 17p Myeloma ModelsSemantic proximity
EPIC-1042 as a potent PTRF/Cavin1–caveolin-1 interaction inhibitor to induce PARP1 autophagic degradation and suppress temozolomide efflux for glioblastomaSemantic proximity
Ribosome Profiling Reveals Translational Reprogramming via mTOR Activation in Omacetaxine Resistant Multiple MyelomaSemantic proximity
P-glycoprotein (P-gp)-driven cancer drug resistance: biological profile, non-coding RNAs, drugs and nanomodulatorsSemantic proximity
Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signalSemantic proximity
Lysin (K)-Specific Demethylase 1 Inhibition Enhances Proteasome Inhibitor Response and Overcomes Drug Resistance in Multiple MyelomaSemantic proximity
Updates to the drug‐resistant mechanism of proteasome inhibitors in multiple myelomaSemantic proximity
The Second-Generation Proteasome Inhibitor Ixazomib Enhances the Anticancer Effects of Gemcitabine or Fluorouracil in Pancreatic Cancer CellsSemantic proximity
A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistanceSemantic proximity
Select a neighboring publication to make it the new centre.